Navigation Links
Two New Jersey Hormone Therapy Lawsuits Dismissed
Date:7/14/2008

MADISON, N.J., July 14 /PRNewswire-FirstCall/ -- Wyeth (NYSE: WYE) announced today that Judge Jamie D. Happas of the New Jersey Superior Court in New Brunswick has granted Wyeth's motion for summary judgment in two hormone therapy cases that were scheduled for trial later this year. The court dismissed the cases of Bailey v. Wyeth, which was to have begun on September 15, and DeBoard v. Wyeth, which had an October 27 trial date. The plaintiffs in both cases alleged they developed breast cancer as a result of the use of Prempro(TM) and Premarin(R), hormone therapy products marketed by Wyeth, as well as Provera(R), a progestin product marketed by Upjohn.

In granting the motions, Judge Happas ruled, among other things, that the plaintiffs "failed to provide the specific type of evidence necessary to overcome the presumption of adequacy afforded [to] FDA-approved labeling" by New Jersey law and that the warnings were "adequate as a matter of law."

"We believe the court's ruling was a proper application of New Jersey law and is consistent with a growing body of law around the nation, rejecting challenges to FDA-approved labeling," says Lauren E. Handler, a partner with Porzio Bromberg & Newman, P.C., a New Jersey-based firm representing Wyeth in both cases.

About Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.


'/>"/>
SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. World Chemical Industry Has Decided to Gather at ChemOutsourcing Show on September 7-9 in New Jersey
2. 60 Specialty Chemical, Fine Chemical & Custom Synthesis Providers Will Exhibit at Pharma ChemOutsourcing on September 8-9 in New Jersey
3. E. coli Outbreak in New Jersey?
4. API and Raw Material Supply Concerns Focal Point of Pharma ChemOutsourcing Conference September 8-9 in New Jersey
5. Chemistry Outsourcing Conference Unveils 90-Speaker Conference Program to Take Place September 8-9 in New Jersey
6. StemCyte Locates East Coast Operations in New Jersey
7. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
8. Novo Nordisk Expands U.S. Headquarters in New Jersey
9. BioSpace New Jersey Career Fair Attracts Over 1,000 Bioscience Candidates
10. NicOx Opens U.S. Headquarters in New Jersey
11. Secure Symbology: Making New Jersey Proud While Saving Lives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)...  Caris Life Sciences, a leading innovator in ... private funder of pancreatic cancer research, are collaborating ... of immunotherapy in the treatment of pancreatic cancer. ... identify potential trial candidates based on biomarker expression ... study investigators. The Lustgarten Foundation is a sponsor ...
(Date:1/18/2017)... Research Future published a half-cooked research report on Global Cancer Diagnostics ... CAGR of 12% during the period 2016 to 2022. ... ... without any control. These abnormal cells have the ability to invade ... spread to other parts of the body through the blood and ...
(Date:1/17/2017)... IA (PRWEB) , ... January 17, 2017 , ... ... China for Balance™ GT soybeans. The new Balance™ GT Soybean Performance System will ... glyphosate and isoxaflutole, the active ingredient in the new Balance® Bean herbicide. The ...
(Date:1/17/2017)... 17, 2017  An international team of researchers ... St. Boniface Hospital Albrechtsen Research Centre/University of Manitoba ... unmet health need affecting nearly one in 15 ... Investigation, their results identify small molecule drugs with ... neuronal injury in animal models of metabolic, chemical ...
Breaking Biology Technology:
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/11/2017)... 2017  Michael Johnson, co-founder of Visikol Inc. a company originally ... been named to the elite "Forbes 30 Under 30" list in ... people in 20 fields nationwide to be recognized as a leader ... were selected. ... is currently a PhD candidate at Rutgers University. ...
(Date:1/4/2017)... -- For the thousands of attendees at this year,s International Consumer Electronics Show ... biometric measurement devices and services, will be featuring its new line of ... Medical,s special CES Exhibit Suite , the new upper arm and ... WellnessConnected product platform.  Continue ... ...
Breaking Biology News(10 mins):